Devanand, D. P., Mintzer, Jacobo, Schultz, Susan K., Andrews, Howard F., Sultzer, David L., de la Pena, Danilo, Gupta, Sanjay, Colon, Sylvia, Schimming, Corbett, Pelton, Gregory H., Levin, Bruce

Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]

Devanand, D. P., Mintzer, Jacobo, Schultz, Susan, Sultzer, David, de la Pena, Danilo, Gupta, Sanjay, Colon, Sylvia, Schimming, Corbett, Pelton, Gregory H., Andrews, Howard, Levin, Bruce

Objectives: : Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients […]

Devanand, D. P., Pelton, Gregory H., Cunqueiro, Karine, Sackeim, Harold A., Marder, Karen

Objective: In patients with Alzheimer’s disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation.; Methods: In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5-5 mg daily) were randomized to a 24-week, double-blind pilot trial of discontinuation on placebo […]